Anxiety Disorder

Neurology·MeSH: Anxiety Disorders

Prevalence

6090.6 / 100K

Incidence

716.2 / 100K/yr

24 drugs in development·19 companies·3 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
buspirone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
Cymbalta®	ELI LILLY & Co (LLY)
duloxetine	Inventiva S.A. (IVA)
lorazepam	ANI PHARMACEUTICALS INC (ANIP)
paroxetine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
paroxetine	Mylan II B.V. (MYL)

Phase 3(7)

Drug	Company
bnc210	Neuphoria Therapeutics Inc. (NEUP)
cyb004	CYBIN INC. (HELP)
effexor sr	Viatris Inc (VTRS)
fasedienol	Vistagen Therapeutics, Inc. (VTGN)
fasedienol nasal spray - fasedienol	Vistagen Therapeutics, Inc. (VTGN)
ph94b	Vistagen Therapeutics, Inc. (VTGN)
vqw-765	Vanda Pharmaceuticals Inc. (VNDA)

Phase 2(8)

Drug	Company
ABBV-932	AbbVie Inc. (ABBV)
antidepressant therapy	AbbVie Inc. (ABBV)
EMP-01	Akari Therapeutics Plc (AKTX)
EMP-01	Atai Beckley N.V. (ATAI)
ENX-102	Valneva SE (VALN)
Fluoxetine	Valneva SE (VALN)
ITI-1284-ODT-SL	Intra-Cellular Therapies, Inc. (ITCI)
psx-001	Incannex Healthcare Inc. (IXHL)

Phase 1(1)

Drug	Company
ART26.12	ARTELO BIOSCIENCES, INC. (ARTL)

Preclinical(2)

Drug	Company
kar-2618	Karuna Therapeutics, Inc. (KRTX)
SPC-15	Silo Pharma, Inc. (SILO)

BioSniper tracks 24 drugs in development for Anxiety Disorder across 19 companies.

There are 3 clinical trials targeting Anxiety Disorder tracked by BioSniper.

The estimated prevalence of Anxiety Disorder is approximately 6090.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.